氟立班丝氨
氟立班丝氨结构式
|
常用名 | 氟立班丝氨 | 英文名 | Flibanserin |
|---|---|---|---|---|
| CAS号 | 167933-07-5 | 分子量 | 390.40200 | |
| 密度 | 1.292 g/cm3 | 沸点 | N/A | |
| 分子式 | C20H21F3N4O | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS06 |
信号词 | Danger |
|
Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.
J. Sex. Med. 8(11) , 3160-72, (2011) Flibanserin is a 5-HT(1A) agonist/5-HT(2A) antagonist that has been shown to increase sexual desire and reduce distress in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD).To assess the efficacy and safety of flibanserin over 24 weeks of doub... |
|
|
Open-label extension study of flibanserin in women with hypoactive sexual desire disorder.
J. Sex. Med. 9(12) , 3180-8, (2012) Hypoactive Sexual Desire Disorder (HSDD) is a common form of Female Sexual Dysfunction characterized by low sexual desire that causes distress or interpersonal difficulty.This 52-week open-label extension study aimed to assess the safety and tolerability of f... |
|
|
Satisfying sexual events as outcome measures in clinical trial of female sexual dysfunction.
J. Sex. Med. 8(12) , 3262-70, (2011) Assessing the sexual response in women with female sexual dysfunctions (FSDs) in clinical trials remains difficult. Part of the challenge is the development of meaningful and valid end points that capture the complexity of women's sexual response.The purpose ... |
|
|
Population pharmacokinetic/pharmacodynamic model for the sedative effects of flibanserin in healthy volunteers.
Pharm. Res. 29(6) , 1518-29, (2012) Flibanserin is being developed for treating hypoactive sexual desire disorder in women; the main side effect is sedation. The analysis objective was to relate flibanserin plasma concentrations with acute sedative effects using a population pharmacokinetic/pha... |
|
|
Compte rendu du congrès 2013 de l’International Society for the Study of Women's Sexual Health (ISSWSH)
Gynecol. Obstet. Fertil. 41(5) , 330-3, (2013)
|
|
|
Resurgence of interest in sexual dysfunction?
BJU Int. 109(11) , E36-7, (2012)
|
|
|
Boehringer Ingelheim withdraws libido drug for women.
BMJ 341 , c5701, (2010)
|
|
|
Dysfunctional women remain unsexed.
BJU Int. 106(3) , 431-2, (2010)
|
|
|
Drug for low sexual desire carries significant harms, FDA advisers find.
BMJ 341 , c3339, (2010)
|
|
|
Flibanserin: initial evidence of efficacy on sexual dysfunction, in patients with major depressive disorder.
J. Sex. Med. 7(10) , 3449-59, (2010) Flibanserin, a novel 5-HT(1A) agonist and 5-HT(2A) antagonist, has the potential to treat sexual dysfunction.Provide historical perspective on the rationale for development of flibanserin to treat sexual dysfunction, based on post hoc analyses of data.The Ari... |